FL-ZYCUS
20.5.2024 15:01:27 CEST | Business Wire | Press release
Zycus, the pioneer in Generative AI-powered Source-to-Pay solutions, ignited a wave of innovation at its annual procurement conference, Horizon 2024. The event showcased a groundbreaking suite of GenAI advancements designed to elevate automation, intelligence, and efficiency throughout the Source-to-Pay (S2P) process.
Zycus Revolutionizes Procurement with Merlin
Zycus introduced a two-pronged approach to GenAI-powered procurement:
- Merlin Assist Chatbot: Integrated with Microsoft Teams, this AI assistant acts as the "front door" to procurement, allowing users to ask questions, extract contract details, generate summaries, develop strategies, and streamline workflows—all within the familiar Teams environment. As we say at Zycus, AI is the new UI.
- Merlin GenAI Power Apps: Delivered through AppXtend, these applications unlock 10x efficiency and effectiveness, addressing critical tasks such as streamlining approvals, automating contract risk management, simplifying sourcing, enhancing Accounts Payable, automating project management, facilitating supplier risk management, and validating reports with Insight Studio.
"Zycus' Merlin GenAI addresses critical pain points across the S2P process, surpassing basic automation like invoice processing or user assignment," said the Head of Indirect Procurement of a Global 500 company at Horizon.
Aatish Dedhia, Founder & CEO of Zycus, highlighted, "With over 20 years of AI-driven innovation including five years with the Merlin AI platform, Zycus has built deep, well-managed datasets, ensuring effective GenAI model training and a nuanced understanding of customer needs. Our AppXtend API framework enables rapid development, deployment, and deep integration of GenAI across S2P processes.”
Industry Validation: Microsoft Recognizes Zycus Leadership
"AI will transform the way individuals, teams, and organizations work," said Samik Roy, Executive Director, Corporate, Medium and Small Businesses, Microsoft India. "Zycus has integrated Azure OpenAI to infuse AI into its daily operations. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus's success."
Zycus Horizon: A Springboard for GenAI Leadership
Horizon 2024 served as a powerful platform for Zycus to demonstrate its leadership in GenAI-powered procurement solutions, empowering businesses with significant efficiency gains, agility, cost savings, and a competitive advantage.
About Zycus:
Zycus is the leader in Source-to-Pay (S2P) solutions, pioneering the world's first Generative AI powered platform that helps procurement achieve 10X speed and efficiency. It has been a trusted partner of choice for large global enterprises and is consistently recognized by leading analysts like Gartner and Forrester.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520570248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration1.7.2026 11:00:00 CEST | Press release
Haleon, a consumer health company solely focused on better everyday health, today announces a new five-year collaboration with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global Win as One strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630342896/en/ The new agreement builds on Haleon’s existing use of Microsoft 365 Copilot and further supports the wider adoption of AI-powered tools across the business, helping teams automate routine tasks, collaborate more effectively and focus on higher-value work. Importantly, it will also further strengthen Haleon’s digital and AI-enabled infrastructure through further adoption of Microsoft’s agentic AI, security and identity capabilities, helping the company to scale AI securely and responsibly. Haleon and Microsoft will co-create high-impact AI use cases which deliver value across multiple critical functions, from
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom